EGFR and non-small cell lung carcinoma: Among these resistant mechanisms, second mutation of EGFR (T790M mutation, the gate keeper position of the kinase domain of EGFR) is best characterized and most commonly occurring, observed in 60% of EGFR-mutant NSCLC patients with acquired resistance to gefitinib and erlotinib [9].